01-17-06

2006			U.S. Pa	atent and Trad	PTO/SB/21 (0s ed for use through 07/31/2006. OMB 0651-0031 demark Office; U.S. DEPARTMENT OF COMME formation unless it displays a valid OMB control num
Under the Paper	WORK Reduction Act of 1995, no	persons are required	Application I		10/617,489
TF	TRANSMITTAL				July 10, 2003
	FORM		First Named	Inventor	Thomas L. CANTOR
/to ho use	d for all correspondence after	initial filing)	Art Unit		1641
(10 be use	a for all correspondence after	muai margy	Examiner N	ame	C. Cheu
Total Number	of Pages in This Submiss	ion 26	Attorney Do	cket Number	532212000623
	EN	CLOSURES	(Check all	that apply	(ע
X Fee Transn duplicate)	nittal Form (1 page plus	Drawing(s)			After Allowance Communication to TC
Fee A	Attached	Licensing-rel	lated Papers		Appeal Communication to Board of Appeals and Interferences
Amendmen	t/Reply	Petition			Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
After	Final		Petition to Convert to a Provisional Application		Proprietary Information
Affida	avits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Address			Status Letter
Extension of	Extension of Time Request		Terminal Disclaimer		X Other Enclosure(s) (please Identify below):
Express At	pandonment Request	Request for Refund			PTO/SB/08a/b Form (8 pages plus duplicate)
X Information (7 pages)	Disclosure Statement	CD, Number of CD(s)			References (188) Return Receipt Postcard
	opy of Priority s)	Landscape Table on CD		CD	
Reply to M	issing Parts/ Application	Remarks		<u></u>	
Repl	y to Missing Parts under FR 1.52 or 1.53	CUSTOMER NO. 25225			
	٠.				6
Firm Name		URE OF APPLIC	ANT, ATTO	RNEY, OR	AGENT
	MORRISON & FOE	RSTER LLP			
Signature	c c				
Printed name	Peng Chen				
Date	January 13, 2006			Reg. No.	43,543

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 761643881 US and EV 761643895 US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below. Dated: January 13, 2006 نام Signature: Mum (Lenay Rogus)

Approved for use through 7/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004.				Complete if Known				
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).				Application Nun	nber	10/617,489		
FEE TRANSMITTAL				Filing Date July 10, 2003				
For FY 2005				First Named Inv	entor	Thomas L. C.	ANTOR	
	FUI F I Z	005		Examiner Name		C. Cheu	·	
X Applicant	claims small entity sta	tus. See 37 CFR 1.2	7	Art Unit		1641		
TOTAL AMOU	NT OF PAYMENT	(\$) 180.00		Attorney Docket	No.	53221200062	23	
METHOD OF	PAYMENT (check	all that apply)						
Check Credit Card Money Order Other (please identify):								
x Deposit Acc	count Deposit Account	Number: 03-1952	Deposit Acc	count Name:	Mc	rrison & Foer	ster LLP	
For the a	above-identified dep	osit account, the D	irector is	s hereby authorize	ed to: (che	eck all that apply	()	
x Ct	narge fee(s) indicate	d below		Charg	e fee(s) in	dicated below,	except for the	filing fee
	narge any additional e(s) under 37 CFR		ment of	x Credit	any overp	payments		
FEE CALCUL	ATION							
1. BASIC FILING	G, SEARCH, AND E	XAMINATION FE	E\$					
	F	ILING FEES	SE	ARCH FEES	EXAMI	NATION FEE	_	
Application Ty	rpe Fee (\$ Small Entity \$) Fee (\$)	Fee (\$	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fees Pa	id (\$)
Utility	300	150	500	250	200	100		
Design	200	100	100	50	130	65		
Plant	200	100	300	150	160	80		
Reissue	.300	150	500	250	600	300		
Provisional	200		0	0	0	0		
2. EXCESS CLA	NM FEES						S	mall Entity
Fee Description							Fee (\$)	Fee (\$)
Each claim over	20 (including Reis	sues)					50	25
	nt claim over 3 (inc	luding Reissues)					200	100
Multiple depend	lent claims						360	180
Total Claims	Extra Claims	Fee (\$)	Fee	Paid (\$)	<u>N</u>	<u>lultiple Depend</u>	dent Claims	
80	- 80 =	× = _			E	ee (\$)	Fee Paid (\$)	
indep. Claims	Extra Claims	Fee (\$)	Fee	Paid (\$)				
	-4=	x =						
3. APPLICATIO								
		exceed 100 sheets	of paper	(excluding electi	ronically i	filed sequence of	or computer	
If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50								
sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).								
<u>Total Sheet</u>			of each a	additional 50 or fra			Fee Pa	<u>iid (\$)</u>
4. OTHER FEE(100 = 'S)	/50		(round up to a who	ole number) ×	Foos D	aid (\$)
I	4. OTHER FEE(S) Non-English Specification, \$130 fee (no small entity discount)							
-	Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement 180.00							
SUBMITTED BY			***					
Signature		19-		Registration No. (Attorney/Agent)	43,543	Telephone	(858) 720	-5117
Name (Print/Type)	Peng Chen			<u> </u>	_	Date	January 13	. 2006

JAN 1 8 2006 B

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill Nos. EV 761643881US and EV 761643895 US addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: January 13, 2006 Signature:

Patent Docket No. 532212000623

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Thomas L. CANTOR

Serial No.: 10/617,489

Filing Date: July 10, 2003

For: METHODS, KITS AND ANTIBODIES

FOR DETECTING PARATHYROID

HORMONE

Examiner: C. Cheu

Group Art Unit: 1641

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicant submits for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of the documents are submitted herewith. The Examiner is requested to make these documents of record.

Document numbers 15-47, 75-93, and 173-187 are from *Nichols Institute Diagnostics*, *Inc. v. Scantibodies Clinical Laboratory Inc. and Scantibodies Laboratory, Inc.*, U.S.D.C. for the Southern District of California, Case No. 02 CV 0046 B (LAB).

01/17/2006 HDESTA1 00000042 031952 10617489

01 FC:1806

180.00 DA

sd-273649



Document numbers 48-61 are from a reexamination proceeding of United States Patent Number 6,689,566 ("the '566 patent") requested by Scantibodies, now assigned control No. 90/007,685. Document numbers 49-60 were cited as exhibits in the Request for Reexamination of the '566 patent by Scantibodies. The present application is a Continuation-in-Part of United States Patent Number 6,743,590 ("the '590 patent"), which is a Continuation-in-Part of the '566 patent.

Document numbers 62-68 are from an opposition proceeding against EP Patent No. 0 783 522. Document numbers 69-72 are from a reexamination proceeding of United States Patent No. 6,030,790, now assigned control No. 90/007,412.

Document numbers 73 and 74 are from another reexamination proceeding of United States Patent Number 6,689,566 ("the '566 patent"), filed by Immutopics, Inc., now assigned control No. 90/007,732.

Document numbers 94-103 are from the prosecution of the Applicant's related EP application No. 00 902 406.8-2404. Document numbers 104-106 are from the prosecution of the Applicant's related Japanese Patent Application No. 2000-593958.

Document numbers 107-171 are from *Scantibodies Laboratory, Inc. v. Immutopics, Inc.*, currently pending in the United States District Court for the Central District of California, Case No. CV04-8871 GPS (MANx). Document numbers 164-171 are bate stamped discovery documents from this litigation.

Document number 172 is from an invalidation proceeding against JP Patent No. 3457004.

This Information Disclosure Statement is submitted:

	With th	ne application; accordingly, no fee or separate requirements are required.
	Before	the mailing of a first Office Action after the filing of a Request for Continued
	Exami	nation under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97
	(e)(1) 1	has been provided.
	Within	three months of the application filing date or before mailing of a first Office Action
	on the	merits; accordingly, no fee or separate requirements are required. However, if
	applica	able, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
\boxtimes	After r	eceipt of a second non-final Office Action on the merits but before mailing of a final
	Office	Action or Notice of Allowance.
		A fee is required. A check in the amount of is enclosed.
	\boxtimes	A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to
		this submission in duplicate.
		A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is
		believed to be due.
	After 1	nailing of a final Office Action or Notice of Allowance, but before payment of the
	issue f	ee.
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the
		amount of is enclosed.
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal
		form (PTO/SB/17 is attached to this submission in duplicate.)

Pursuant to MPEP § 2004.13, Applicant points out that Nichols Institute Diagnostics Inc. (Nichols) has sued the assignee of the present application, Scantibodies Laboratory, Inc. (Scantibodies) for alleged infringement of U.S. Patent No. 6,030,790 ('790 patent). The '790 patent was submitted and considered by the Examiner in the prosecution of the parent patents of the present application, U.S. Patent No. 6,689,566 B1 (the '566 patent) and U.S. Patent No. 6,743,590 B1 ('590 patent). The '790 patent was also submitted in the February 25, 2004 IDS (Reference No.

11) and considered by the Examiner in connection with the present application (See the January 24, 2005 Office Action). Applicant wishes to bring the Examiner's attention to the following:

- After a jury trial, the U.S. District Court for the Southern District of California in San Diego entered a judgment based on the jury verdict that claims 1-25 of the '790 patent are invalid for lack of enablement, lack of written description and failure to disclose the best mode (See Document No. 181 submitted with the July 7, 2005 Supplemental IDS);
- The Court vacated the jury verdict in an Order Re: Post-Verdict Motions, filed August 30, 2005 (Document No. 47 of the present Supplemental IDS);
- The Court issued Settled Findings of Fact and Conclusions of Law on Inequitable Conduct and Order Adjudicating Patent Enforceable, filed October 14, 2005
 (Document No. 76 of the present Supplemental IDS);
- The Court issued an Order Granting Nichols' Motion for Entry of Permanent Injunction and Staying Injunction Pending Appeal, filed November 16, 2005 (Document No. 186 of the present Supplemental IDS);
- Scantibodies filed an Emergency Motion To Stay Injunction and Damages/Willfulness Trial Pending Appeal on November 17, 2005 (Document No. 91 of the present Supplemental IDS); and
- December 16, 2005 Transcript of Damages Trial showing the jury verdict (Document No. 187 of the present Supplemental IDS).

Scantibodies has requested reexamination of the '790 patent (Document No. 66 submitted with the May 10, 2005 Supplemental IDS) and the U.S. PTO ordered the reexamination of the '790 patent (Document No. 67 submitted with the May 10, 2005 Supplemental IDS). The U.S. PTO issued the first non-final Office Action in the *Ex Parte* Reexamination of U.S. Patent 6,030,790 (Control No. 90/007,412) on September 28, 2005 (Document No. 69 of the present

Supplemental IDS), Nichols filed a First Amendment and Response to Reexamination Office Action on November 28, 2005 (Document No. 71); and

One of the listed inventors of the '790 patent is Markus Magerlein. The Magerlein Ph.D. Dissertation and its English translation are submitted herewith (Document Nos. 8 and 9 of the present Supplemental IDS). The Magerlein Ph.D. Dissertation discloses detection of various PTH fragments and intact PTH (1-84) apparently at a concentration of 8 to 500 pmol/l (*See* Document No. 9 of the present Supplemental IDS at pages 59-60 (PHA003936-PHA003937).

Scantibodies is opposing the '790 patent's corresponding patent in Europe, EP Patent No. 0 783 522 in the EPO, and commenced an invalidation proceeding against the '790 patent's corresponding patent in Japan, JP Patent No. 3457004, in the JPO. The JPO has invalidated JP Patent No. 3457004 (Document No. 172 of the present Supplemental IDS)¹.

Scantibodies commenced a civil action for patent infringement based on the '566 patent: Scantibodies v. Immutopics. Applicant wishes to bring the Examiner's attention to the following:

- Scantibodies requested reexamination of the '566 patent (Document No. 48 of the present Supplemental IDS). Document Nos. 49-60 were cited as exhibits in Scantibodies' Request for Reexamination of the '566 patent. The U.S. PTO ordered the reexamination of the '566 patent based on Scantibodies' Request (control No. 90/007,685) (Document No. 61 of the present Supplemental IDS).
- The District Court in the *Scantibodies v. Immutopics* case issued an Order Granting Plaintiff's Motion To Stay Proceedings on September 20, 2005 (Document No. 161 of the present Supplemental IDS).

Immutopics filed a Request for *Ex Parte* Reexamination of U.S. Patent 6,689,566 per Rule 1.501 et seq. on September 28, 2005 (Document No. 73 of the present Supplemental IDS). Immutopics' Request is based on the following documents:

¹ Nichols can still appeal the JPO's decision within the JPO.

- US Patent No. 6,689,566 (The present application is a Continuation-in-Part of US Patent No. 6,743,590, which is a Continuation-in-Part of US Patent No. 6,689,566);
- Order Re: Post Verdict Motions, filed August 30, 2005 (Document No. 47 of the present Supplemental IDS);
- Declaration of Richard A. Lerner, M.D., In Support Of Motion For Summary
 Judgment Pursuant To 35 U.S.C. § 102(b) By Defendants Scantibodies Clinical
 Laboratory, Inc. And Scantibodies Laboratory Inc., filed February 25, 2003
 (Document No. 118 of the Supplemental IDS submitted on May 10, 2005);
- Declaration of J. Stuart Woodhead, Ph.D., In Support Of Motion For Summary
 Judgment Pursuant To 35 U.S.C. § 102(b) By Defendants Scantibodies Clinical
 Laboratory, Inc. And Scantibodies Laboratory Inc., filed February 25, 2003
 (Document No. 119 of the Supplemental IDS submitted on May 10, 2005);
- Colford, 1997 Abstract Presentation to the Endocrine Society, 79th Annual Meeting, June 11-14, 1997 at Minneapolis, Minnesota (Document Numbers 49 and 57 of the present Supplemental IDS);
- Magerlein et al., Pharmaceutical Sciences 2 (1994) 117-194, page 142
 (Document No. 35 of the Supplemental IDS submitted on May 10, 2005);
- Tampe et al., Journal of Immunoassay (1992) 13(1):1-13 (Document No. 19 of the Supplemental IDS submitted on July 7, 2005);
- Kohno et al., Journal of Clinical Laboratory Analysis (1998) 12:268-275
 (Document No. 54 of the present Supplemental IDS);
- US Patent No. 6,030,790 (Document No. 11 of the IDS submitted on February 25, 2004 and document No. 2 of the Supplemental IDS submitted on July 7, 2005).

The U.S. PTO ordered the reexamination of the '566 patent based on Immutopics' Request (control No. 90/007,732) (Document No. 74 of the present Supplemental IDS).

Applicant would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing <u>532212000623</u>.

Dated: January <u>1</u>3, 2006

Respectfully submitted,

By Chen

Peng Chen
Registration

Registration No.: 43,543 MORRISON & FOERSTER LLP 12531 High Bluff Drive

Suite 100

San Diego, California 92130-2040

(858) 720-5117

Sheet

stitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known				
Application Number	10/617,489			
Filing Date	July 10, 2003			
First Named Inventor	Thomas L. CANTOR			
Art Unit	1641			
Examiner Name	C. Cheu			
Attorney Docket Number	532212000623			

	U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.¹	Foreign Patent Document Country Code ³ -Number Hind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	1.	BROSSARD et al., Journal of Clinical Endocrinology and Metabolism (1993) 77:413-419	
	2.	CAETANO et al., Equus Genome Res. (1999) 9(12):1239-1249	
	3.	D'AMOUR et al., J. Bone Miner. Res. (1996) 11:1075-1085	
	4.	FUHR et al., Klin Wochenschr (1955) 33:729-730	
	5.	FUJIMORI et al., Therapeutic Apheresis and Diálysis (2004) 8(6):474-479	
	6.	K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, Draft Guideline Statements and Treatment Algorithms, February 2003	
	7.	KOHLER and MILSTEIN, Nature (1975) 256:495-497	
	8.	MAGERLEIN, Ph.D. Dissertation, October 31, 1995, Ruprecht Karls University of Heidelberg (Original in German)	
	9.	MAGERLEIN, Ph.D. Dissertation, October 31, 1995, Ruprecht Karls University of Heidelberg (English Translation)	
	10.	MALLUCHE, The Importance of Bone Health in ERSD: Out of the Frying Pan, Into the Fire?, World Congress on Nephrology, Berlin, Germany, June 2003	
	11.	MAYER et al., Endocrinology (1979) 104:1778-1784	
	12.	WATSON et al., Molecular Biology of the Gene, 4 th edition, (1987) The Bejamin/Cummings Pub. Co., page 224	
	13.	WOOD et al., PNAS USA (1985) 82:1585-1588	
	14.	WOODHEAD, Clin. Biochem. (1990) 23:17-21	
	15.	Scantibodies' Notice of Motion and Motion For Summary Judgment of Invalidity and Noninfringement, filed February 18, 2005	
	16.	Declaration of Randolph Wall, PHD in Support of Scantibodies' Memorandum of Points and Authorities in Support of Motion for Summary Judgment of Invalidity and Noninfringement, filed February 18, 2005	
	17.	Declaration of Dr. Wolf Grosskopf in Support of Motion For Summary Judgment of Invalidity	

Examiner	Date	
Signature	Considered	
nd 070007		

Complete if Known Substitute for form 1449/PTO 10/617,489 Application Number **INFORMATION DISCLOSURE** Filing Date July 10, 2003 **STATEMENT BY APPLICANT** Thomas L. CANTOR First Named Inventor Art Unit 1641 (Use as many sheets as necessary) Examiner Name C. Cheu Sheet 2 of 8 Attorney Docket Number 532212000623

	and National Stad Fahrum 40,000	
- I	and Noninfringement, filed February 18, 2005	_
18.	[Proposed] Order Granting Scantibodies' Motion for Summary Judgment of Invalidity and Noninfringement, filed February 18, 2005	
19.	Declaration of K. Ramakrishan, PH.D. in Support of Nichols Institute Diagnostics, Inc.'s	
	Opposition to Motion For Summary Judgment of Invalidity and Non-Infringement, filed March 7, 2005	
20.	Declaration of Eva Guthrie in Support of Nichols Institute Diagnostics, Inc.'s Opposition to Motion For Summary Judgment of Invalidity and Non-Infringement, filed March 7, 2005	
21.	Declaration of John E. Peterson in Support of Nichols Institute Diagnostics, Inc.'s Opposition to Motion For Summary Judgment of Invalidity and Non-Infringement, filed March 7, 2005	
22.	Reply Memorandum of Points and Authorities in Support of Scantibodies' Motion For Summary Judgment of Invalidity and Noninfringement, filed March 14, 2005	
23.	Notice Of Motion and Motion For Nichols Institute Diagnostics, Inc.'s Renewed Motion For Judgment As A Matter Of Law, filed July 13, 2005	
24.	Memorandum Of Points And Authorities In Support Of Nichols Institute Diagnostics, Inc.'s Renewed Motion For Judgment As A Matter Of Law, filed July 13, 2005	
25.	Declaration of April M. Alex In Support Of Nichols Institute Diagnostics, Inc.'s Renewed Motion For Judgment As A Matter Of Law, filed July 13, 2005	
26.	[Proposed] Order Granting Nichols Institute Diagnostics, Inc.'s Renewed Motion For Judgment As A Matter Of Law, filed July 13, 2005	
27.	Memorandum Of Points And Authorities In Support Of Nichols Institute Diagnostics, Inc.'s Motion For A New Trial, filed July 13, 2005	
28.	Declaration of Charles B. Cohler In Support Of Nichols Institute Diagnostics, Inc.'s Motion For A New Trial, filed July 13, 2005	
29.	Declaration of Julia A. Miller In Support Of Nichols Institute Diagnostics, Inc.'s Motion For A New Trial, filed July 13, 2005	
30.	Scantibodies' Notice of Motion and (1) Motion For Relief From Judgment of Infringement As To Claims 17 and 21 and (2) Renewed Motion For Judgment As A Matter Of Law, filed July 14, 2005	
31.	Scantibodies' Memorandum Of Points And Authorities In Support Of (1) Motion For Relief From Judgment of Infringement As To Claims 17 and 21 and (2) Renewed Motion For Judgment As A Matter Of Law, filed July 14, 2005	
32.	Declaration of M. Andrew Woodmansee In Support Of (1) Motion For Relief From Judgment of Infringement As To Claims 17 and 21 and (2) Renewed Motion For Judgment As A Matter Of Law, filed July 14, 2005	
33.	Declaration of M. Andrew Woodmansee In Support Of Scantibodies' Application To Tax Costs, filed July 14, 2005	
34.	Scantibodies' Consolidated Opposition To Nichols' Motion For Judgment As A Matter Of Law And Nichols' Motion For New Trial, filed August 1, 2005	
35.	Declaration Of M. Andrew Woodmansee In Support Of Scantibodies' Consolidated Opposition To Nichols' Motion For Judgment As A Matter Of Law And Nichols' Motion For New Trial, filed August 1, 2005	
36.	Nichols Institute Diagnostics, Inc.'s Opposition To Scantibodies' (1) Motion For Relief From Judgment Of Infringement As To Claims 17 and 21 And (2) Motion For Judgment As A Matter Of Law, filed August 1, 2005	
37.	Declaration of April M. Alex In Support Of Nichols Institute Diagnostics, Inc.'s Opposition To Scantibodies' (1) Motion For Relief From Judgment Of Infringement As To Claims 17 and 21 And (2) Motion For Judgment As A Matter Of Law, filed August 1, 2005	

Examiner	Date
Signature	Considered
24 272607	

Complete if Known Substitute for form 1449/PTO 10/617,489 Application Number **INFORMATION DISCLOSURE** Filing Date July 10, 2003 STATEMENT BY APPLICANT First Named Inventor Thomas L. CANTOR 1641 Art Unit (Use as many sheets as necessary) Examiner Name C. Cheu Sheet 3 of 8 Attorney Docket Number 532212000623

38.	[Proposed] Order Denying Scantibodies' Motion For Judgment As A Matter Of Law, filed August 1, 2005	
39.	Opposition Of Nichols Institute Diagnostics, Inc. To Application To Tax Costs, filed August 1, 2005	
40.	Scantibodies' Reply Brief In Support Of (1) Motion For Relief From Judgment Of Infringement As To Claims 17 and 21 And (2) Renewed Motion For Judgment As A Matter Of Law, filed August 8, 2005	
41.	Declaration of M. Andrew Woodmansee In Support Of Scantibodies' Reply Brief In Support Of (1) Motion For Relief From Judgment Of Infringement As To Claims 17 and 21 And (2) Renewed Motion For Judgment As A Matter Of Law, filed August 8, 2005	
42.	Nichols Institute Diagnostics, Inc.'s Reply To Scantibodies' Opposition To Nichols Renewed Motion For Judgment As A Matter Of Law, filed August 8, 2005	
43.	Declaration of April M. Alex In Support Of Nichols Institute Diagnostics, Inc.'s Reply To Scantibodies' Opposition To Nichols Renewed Motion For Judgment As A Matter Of Law, filed August 8, 2005	
44.	Reply To Scantibodies' Opposition To Nichols Motion For A New Trial, filed August 8, 2005	
45.	Declaration Of Katherine L. Parker In Support Of Scantibodies' Opposition To Nichols' Motion To Retax Costs, filed August 23, 2005	
46.	Reply Memorandum In Support Of Nichols Institute Diagnostics, Inc.'s Motion To Retax Costs, filed August 29, 2005	-
47.	Order Re: Post-Verdict Motions, filed August 30, 2005	
48.	Request For Ex Parte ReExamination of United States Patent Number 6,689,566, filed August 22, 2005	
49.	COLFORD et al., The Endocrine Society, Programs & Abstracts, 79th Annual Meeting, June 11-14, 1997, Minneapolis Minnesota, "Isolation and Characterization of Large Molecular Weight Fragments of PTH"	
50.	COLFORD et al., J. Bone & Miner. Res. (1997) 12(Supp. 1):S318 (F368)	_
51.	COLFORD et al., Clin. Chem. (1997) 43(6):S189 (381)	
52.	COLFORD et al., 10th International Congress of Endocrinology Program and Abstracts (1996), entitled "Data Suggesting the Presence of a Circulating Inhibitor to PTH"	
53.	COLFORD et al., Meeting of the Endocrine Society (1996), entitled "Comparing Specificity For Intact Human Parathyroid Hormone Between INCSTAR PTHSP and Nichols Intact PTH Assays"	
54.	KOHNO et al., J. Clin. Lab. Anal. (1998) 12:268-275	
55.	Defendants' Second Amended Answer To Plaintiff's Complaint And Counterclaims, filed December 31, 2004	
56.	Letter from Immutopics' counsel to Scantibodies' counsel dated August 5, 2005	_
57.	COLFORD 1997 Abstract Presentation	_
58.	JENSEN et al., poster from the 1996 Annual Meeting of the Endocrine Society, San Francisco, CA, entitled "Comparing Specificity For Intact Human Parathyroid Hormone Between INCSTAR PTHSP and Nichols Intact PTH Assays"	
59.	Declaration of John Colford	
60.	GAO et al., J. Bone Miner. Res. (2001) 16(4):605-614	
61.	Order Granting Request For Ex Parte Reexamination for U.S. Patent No. 6,689,566, mailed on September 14, 2005, control No. 90/007,685	
62.	Written Submissions In Preparation Of The Oral Proceedings Scheduled For November 15, 2005, submissions dated September 15, 2005	

Examiner	Date
Signature	Considered
	Considered

Sub	stitute for form 1449/PTO				Complete if Known
				Application Number	10/617,489
IN	IFORMATION	l DI	SCLOSURE	Filing Date	July 10, 2003
S	STATEMENT BY APPLICANT			First Named Inventor	Thomas L. CANTOR
				Art Unit	1641
	(Use as many sh	eets as	necessary)	Examiner Name	C. Cheu
Sheet	4	of	8	Attorney Docket Number	532212000623

63.	Petition Filed by Von Kreisler Selting Werner with the European Patent Office on 15 September 2005	
64.	English Translation of the Petition Filed by Von Kreisler Selting Werner with the European	
	Patent Office on 15 September 2005	
65.	Official Communication by the European Patent Office on 29 September 2005	
66.	English Translation of the Official Communication by the European Patent Office on 29 September 2005	
67.	Petition filed by Patentee in response to the Official Communication dated September 29, 2005 (in German)	
68.	Brief Communication from the Opposition Division dated October 5, 2005 (in German)	
69.	Office Action in Ex Parte Reexamination of U.S. Patent 6,030,790, Control No. 90/007,412, mailed on September 28, 2005	
70.	HARLOW et al., Antibodies, 1988, pp. 366, 428, 584, and 579	
71.	First Amendment and Response to Reexamination Office Action, filed November 28, 2005	
72.	Information Disclosure Statement for Rexamination No. 90/007,412, filed November 28, 2005	
73.	Request for Ex Parte Reexamination of U.S. Patent 6,689,566 per Rule 1.501 et seq., filed on September 28, 2005 by Immutopics	
74.	Order Granting Request for Reexamination of U.S. Patent 6,689,566, mailed on October 27, 2005, control No. 90/007,732	
75.	Declaration of John E. Peterson in Support of Nichols Institute Diagnostics. Inc.'s Motion for Permanent Injunction, filed September 22, 2005	
76.	Settled Findings of Fact and Conclusions of Law on Inequitable Conduct and Order Adjudicating Patent Enforceable, filed October 14, 2005	
77.	Scantibodies' Memorandum of Points and Authorities in Support of Opposition to Nichols' Motion for Permanent Injunction, filed October 14, 2005	
78.	Declaration of Katherine L. Parker in Support of Scantibodies' Opposition to Nichols' Motion for Permanent Injunction, filed October 14, 2005	
79.	Declaration of Allen Garrett in Support of Scantibodies' Opposition to Nichols' Motion for Permanent Injunction, filed October 14, 2005	
80.	Declaration of Dr. Hartmut Malluche in Support of Scantibodies' Opposition to Nichols' Motion for Permanent Injunction, filed October 14, 2005	
81.	Declaration of Dr. Richard Amerling in Support of Scantibodies' Opposition to Nichols' Motion for Permanent Injunction, filed October 14, 2005	
82.	Declaration of Dr. James Tumlin in Support of Scantibodies' Opposition to Nichols' Motion for Permanent Injunction, filed October 14, 2005	
83.	Declaration of Dr. Hassan Fehmi in Support of Scantibodies' Opposition to Nichols' Motion for Permanent Injunction, filed October 14, 2005	
84.	Declaration of Dr. Clarence Wheeler in Support of Scantibodies' Opposition to Nichols' Motion for Permanent Injunction, filed October 14, 2005	
85.	Nichols Institute Diagnostics, Inc.'s Reply Motion for a Permanent Injunction, filed October 24, 2005	
86.	Declaration of Dr. Delbert A. Fisher in Support of Nichols Institute Diagnostics, Inc.'s Reply Motion for a Permanent Injunction, filed October 24, 2005	
87.	Declaration of Dr. Claude Arnaud in Support of Nichols Institute Diagnostics, Inc.'s Reply Motion for a Permanent Injunction, filed October 24, 2005	
88.	Declaration of Katherine L. Parker in Support of Opposition To Nichols' Motion For Clarification of the Court's Order Dated August 30, 2005 Regarding Motion In Limine No. 5, filed October	

Examiner	Date
Signature	Considered
	Considered

Complete if Known Substitute for form 1449/PTO Application Number 10/617,489 **INFORMATION DISCLOSURE** Filing Date July 10, 2003 STATEMENT BY APPLICANT First Named Inventor Thomas L. CANTOR Art Unit 1641 (Use as many sheets as necessary) C. Cheu **Examiner Name** Sheet 5 of 8 532212000623 Attorney Docket Number

	24, 2005	
89.	Nichols Institute Diagnostics, Inc.'s Objections To and Ex Parte Application to Strike Statements Filed in Support of Scantibodies' Opposition to Nichols' Motion for a Permanent Injunction, filed October 25, 2005	
90.	Scantibodies' Opposition to Nichols' Objections To and Ex Parte Application to Strike Statements Filed in Support of Scantibodies' Opposition to Nichols' Motion for a Permanent Injunction, filed October 27, 2005	
91.	Scantibodies' Emergency Motion To Stay Injunction and Damages/Willfulness Trial Pending Appeal, filed November 17, 2005	
92.	Appellant's Appendix to Scantibodies' Emergency Motion To Stay Injunction and Trial Pending Appeal, filed November 17, 2005	
93.	Federal Circuit Appeal Information Sheet, filed November 17, 2005	
94.	Office Action – Examination Report dated July 14, 2003 for EP application No. 00 902 406.8-2404	
95.	Response to Office Action – Examination Report dated July 14, 2003, response dated January 23, 2004	
96.	Office Action – Examination Report dated March 16, 2004, for EP application No. 00 902 406.8-2404	
97.	Response to Office Action – Examination Report dated March 16, 2004, response dated September 8, 2004	
98.	Office Action – Examination Report dated May 6, 2005, for EP application No. 00 902 406.8-2404	
99.	Written Submissions prior to the Oral Proceedings, dated September 15, 2005	
100.	Letter from counsel following phone conference with examiner and in anticipation of Oral Proceedings, dated October 4, 2005	
101.	Result of Consultation of September 29, 2005, dated October 12, 2005	
102.	Result of Consultation of October 4, 2005, dated October 12, 2005	
103.	Minutes of the Oral Proceedings on October 17, 2005, dated November 9, 2005	
104.	Official Action (and English Translation) for Japanese Patent Application No. 2000-593958, mailed on August 13, 2004	
105.	Partial Translation of the Response filed February 9, 2005	
106.	Decision of Rejection (and English Translation) for Japanese Patent Application No. 2000-593958, mailed on August 9, 2005	
107.	Plaintiff's Responses To Defendants' First Set Of Interrogatories Pursuant To Fed. R. Civ. P. 33 (Nos. 1-4), filed April 22, 2005	
108.	Plaintiff's Responses To Defendants' First Set Of Requests For Admissions Pursuant To Fed. R. Civ. P. 36 (Nos. 1-11), filed April 22, 2005	
109.	Defendants' Second Request For Admissions To Plaintiff Pursuant To Fed. R. Civ. P. 36 (No. 12-21), filed June 8, 2005	
110.	Application For An Order For The Issuance Of Letter Rogatory; Memorandum Of Points And Authorities; Declaration Of Dan P. Sedor, filed June 9, 2005	
111.		
112.	Scantibodies' Second Set Of Interrogatories To Defendants/Counterclaimants Immutopics, Inc. And Immutopics International, LLC (Nos. 15-19) filed June 10, 2005	
113.	Scantibodies' Second Request For Production Of Documents To Defendants/Counterclaimants Immutopics, Inc. And Immutopics International, LLC (Nos. 64-69) filed June 10, 2005	

Examiner	Date
Signature	Considered

Su	bstitute for form 1449/PTO			Complete if Known		
				Application Number	10/617,489	
	NFORMATION	N DIS	SCLOSURE	Filing Date	July 10, 2003	
S	STATEMENT I	3Y A	PPLICANT	First Named Inventor	Thomas L. CANTOR	
				Art Unit	1641	
	(Use as many sh	eets as	necessary)	Examiner Name	C. Cheu	
Sheet 6 of 8			8	Attorney Docket Number	532212000623	

	114.	Scantibodica' First Doguest For Admissions To Defendants/Counterplains at 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
¹	14.	Scantibodies' First Request For Admissions To Defendants/Counterclaimants Immutopics, Inc.	
· .		And Immutopics International, LLC)Nos. 1-110), filed June 10, 2005	
	115.	Objections Of Third-party Respondent Richard E. Reitz. M.D., filed June 13, 2005	
1	116.	Notice Of Deposition Of Scantibodies Laboratory, Inc. Pursuant To F.R.C.P. 30(b)(6), filed	
		June 17, 2005	
ļ 1	l 17.	Scantibodies' Third Request For Production Of Documents To Defendants/Counterclaimants	
		Immutopics, Inc. And Immutopics International, LLC (No. 70) filed July 1, 2005	
1	118.	Plaintiff/Counterdefendant's Objections To Defendant/Counterclaimant's Deposition Notice	
		Pursuant To F.R.C.P. 30(B)(6), filed July 8, 2005	
1	119.	Plaintiff's Responses To Defendants' Second Set Of Interrogatories Pursuant To Fed. R. Civ.	
		P. 33 (No. 5), filed July 12, 2005	
1	120.	Responses To Defendants' Second Request For Admissions To Plaintiff Pursuant To Fed. R.	_
1		Civ. P. 36 (Nos. 12-21), filed July 12, 2005	
1	121.	Defendants' Third Request For Admissions To Plaintiff Pursuant To Fed. R. Civ. P. 36 (Nos.	_
l '		22-23), filed July 12, 2005	
1	122.	Defendants/Counterclaimants' Response To Scantibodies' First Requests For Admissions	_
'		(Nos. 1-110), filed July 12, 2005	
1	123.	Defendants/Counterclaimants' Response To Scantibodies' Second Request For Production Of	—
I '	120.	Documents (Nos. 64-69), filed July 13, 2005	
 	124.	Defendants' Fourth Request For Admissions To Plaintiff Pursuant To Fed. R. Civ. P. 36 (Nos.	
l l'	124.	24-37), filed July 15, 2005	
l	105		
	125.	Objections To Subpoena And Notice Of Deposition Of Peng Chen, filed July 25, 2005	
1	126.	Defendants' Fifth Request For Admissions To Plaintiff Pursuant To Fed. R. Civ. P. 36 (Nos.	
-		38-47), filed July 27, 2005	
]	127.	Scantibodies' Third Set Of Interrogatories To Defendants/Counterclaimants Immutopics, Inc.	
		And Immutopics International, LLC (Nos. 20-24), filed August 1, 2005	
1	128.	Scantibodies' Second Request For Admissions To Defendants/Counterclaimants Immutopics,	
L		Inc. And Immutopics International, LLC (Nos. 111-276), filed August 1, 2005	
 	129.	Scantibodies' Fourth Request For Production Of Documents And Things To	
		Defendants/Counterclaimants Immutopics, Inc. And Immutopics International, LLC (Nos. 71-	
		88), filed August 1, 2005	
1	130.	Defendants/Counterclaimants' Response To Scantibodies' Third Request For Production Of	
		Documents (No. 70), filed August 1, 2005	
1	131.	Plaintiff's Response To Defendants' Third Request For Admissions Pursuant To Fed. R. Civ.	
		P. 36 (Nos. 22-23), filed August 11, 2005	
1	132.	Plaintiff's Response To Defendants' Fourth Request For Admissions Pursuant To Fed. R. Civ.	
		P. 36 (Nos. 24-37), filed August15, 2005	
1	133.	Notice Of Service Deposition Subpoena And Subpoena Duces Tecum On Michael A. Levine,	
		filed August 16, 2005	
1	134.	Notice Of Service Subpoena Duces Tecum On Lori J. Sokoll, filed August 16, 2005	
	135.	Notice Of Service Of Subpoena Duces Tecum On Diasorin Inc., filed August 16, 2005	_
	136.	Notice Of Service Of Subpoena Duces Tecum On The Johns Hopkins Medical Institutions,	_
		filed August 16, 2005	
1	137.	Defendants/Counterclaimants' Response To Scantibodies' Second Set Of Interrogatories	
		(Nos. 15-19), filed August 16, 2005	
 	138.	Notice Of Service Of Deposition Subpoena And Subpoena Duces Tecum on John W. Colford,	
<u> </u>	100.	filed August 17, 2005	
		Tilled Adgust 17, 2000	

Examiner	Date
Signature	Considered

Complete if Known Substitute for form 1449/PTO 10/617,489 Application Number **INFORMATION DISCLOSURE** Filing Date July 10, 2003 **STATEMENT BY APPLICANT** Thomas L. CANTOR First Named Inventor 1641 Art Unit (Use as many sheets as necessary) C. Cheu Examiner Name 7 532212000623 Sheet of 8 Attorney Docket Number

	139.	Notice Of Service Of Deposition Subpoena And Subpoena Duces Tecum on Michael Salvati, filed August 17, 2005
	140.	Declaration Of M. Andrew Woodmansee In Support Of Motion To Quash Immutopics' Subpoena To Third-Party Dr. Richard Lemer And For Attorneys' Fees, filed August 18, 2005
	141.	Notice Of Service Of Deposition Subpoena And Subpoena Duces Tecum On Gordon D. Macfarlane, filed August 18, 2005
	142.	Declaration Of John Colford, dated August 18, 2005
	143.	Memorandum Of Points And Authorities In Support Of Plaintiff's Motion To Stay Action Pending Resolution Of Plaintiff's Request To Patent And Trademark Office For Reexamination Of Patent-In-Suit, filed August 22, 2005
	144.	Declaration Of Brian W. Kasell In Support Of Plaintiff's Motion To Stay Action Pending Resolution Of Plaintiff's Request To Patent And Trademark Office For Reexamination Of Patent-In-Suit, filed August 22, 2005
•	145.	Stipulation Regarding Briefing Schedule For Plaintiff's Motion To Stay Action Pending Resolution Of Plaintiff's Request To Patent And Trademark Office For Reexamination Of Patent-In-Suit [Proposed] Order Thereon, filed August 22, 2005
	146.	Notice Of Service Of Subpoena Duces Tecum On Diasorin Inc., filed August 24, 2005
	147.	Notice Of Service Of Subpoena Duces Tecum On Todd Jensen, filed August 24, 2005
	148.	Notice Of Service Of Subpoena Duces Tecum On Jon Spring, filed August 24, 2005
	149.	Plaintiff's Response To Defendants' Fifth Request For Admissions Pursuant To Fed. R. Civ. P. 36 (Nos. 38-47), filed August 25, 2005
	150.	Defendants/Counterclaimants' Response To Scantibodies' Third Set Of Interrogatories (Nos. 20-24), filed August 31, 2005
	151.	Defendants/Counterclaimants' Response To Scantibodies' Fourth Request For Production Of Documents (Nos. 71-88), filed August 31, 2005
	152.	Defendant/Counterclaimants' Response To Scantibodies' Second Request For Admissions (Nos. 111-276), filed August 31, 2005
	153.	Defendant's Opposition To Motion To Stay Action Pending Resolution Of Re-examination Of Patent-In-Suit, filed September 2, 2005
	154.	Declaration Of Matthew Newboles In Support Of Defendant's Opposition For Motion To Stay, filed September 2, 2005
	155.	Declaration Of Richard Zahradnik In Support Of Defendants' Opposition For Motion To Stay, filed September 2, 2005
	156.	Plaintiff's Evidentiary Objections To And Request To Strike The Declarations Of Matthew Newboles And Richard Zahradnik And A Portion Of Defendants' Opposition Memorandum In Support Of Defendants' Opposition To Plaintiff's Motion For Stay, filed September 12, 2005
	157.	Declaration Of David Cantor In Support Of Plaintiff's Reply To Defendants' Opposition To Plaintiff's Motion To Stay, filed September 12, 2005
	158.	Supplemental Declaration Of Richard Zahradnik In Support Of Defendants' Opposition For Motion To Stay, filed September 15, 2005
	159.	Request For Judicial Notice Of Recently Discovered Ruling, Re: Motion For Stay, filed September 15, 2005
	160.	Plaintiff's Evidentiary Objections To And Request To Strike The Supplemental Declaration Of Richard Zahradnik In Support Of Defendants' Opposition To Plaintiff's Motion For Stay, filed September 19, 2005
	161.	Order Granting Plaintiff's Motion To Stay Proceedings, filed September 20, 2005
	162.	Notice Of Patent And Trademark Office's Grant Of Plaintiff's Request For Reexamination, filed

Examiner	Date	•
Signature	Considered	

Sub	estitute for form 1449/PTO				Complete if Known
				Application Number	10/617,489
11	(Use as many sheets as necessary)	SCLOSURE	Filing Date	July 10, 2003	
STATEMENT BY APPLICANT			APPLICANT	First Named Inventor	Thomas L. CANTOR
	STATEMENT BY APPLICAN			Art Unit	1641
	(Use as many sh	èets as	s necessary)	Examiner Name	C. Cheu
Sheet	8	of	8	Attorney Docket Number	532212000623

		September 22, 2005	
*	163.	Bate Stamped Documents Index	
	164.	BioActive Intact PTH Assays, bate stamped IMU-2839-2840	
	165.	Human BioActive Intact PTH ELISA Kit, bate stamped IMU-2841-2844	
	166.	Human BioActive PTH 1-84 ELISA Kit, bate stamped IMU-2845-2846	
	167.	PTH (1-84) Specific Label, bate stamped SC 010159	
	168.	Human BioActive PTH 1-84 ELISA Kit Label, bate stamped SC 010163	
	169.	Whole PTH (1-84) Specific Label, bate stamped SC 010168	
	170.	NKF 2004 PTH Abstracts, bate stamped SC 01483-01496	
	171.	The Rise In Adynamic Bone Disease In ERSD Patients and the Changing Spectrum of Renal	_
		Osteodystrophy, bate stamped SC 001268-001276	
	172.	Judgment for the Invalidation of Japanese Patent No. 3457004, cover letter dated December 7, 2005	
	173.	Petition For Writ Of Mandamus, filed November 23, 2005	
·.	174.	Nichols Institute Diagnostics, Inc.'s Proposed Single Paragraph Informing Jury Of Posture Of The Case, filed November 29, 2005	
	175.	[Proposed] Jury Instructions Of Plaintiff Nichols Institute Diagnostics, Inc., filed November 29, 2005	
	176.	Scantibodies' Proposed Jury Instructions For December 5, 2005 Damages And Willfulness Trial, filed November 29, 2005	
	177.	Declaration of April M. Alex In Support Of Plaintiff's Statement Of Position On Scantibodies' Claims Of Privilege, As The Result Of The Court's Statements About Knorr-Bremse At The Hearing Of November 7, 2005, filed November 30, 2005	
	178.	Nichols' Response To Scantibodies' Emergency Motion To Stay Injunction Pending Appeal, field December 1, 2005	
	179.	Appendix To Nichols' Response To Scantibodies' Emergency Motion To Stay Injunction Pending Appeal, field December 1, 2005	
	180.	Nichols' Seventh Amended Exhibit List To Memorandum Of Fact And Law, filed December 4, 2005	
	181.	Nichols' Eighth Amended Exhibit List To Memorandum Of Fact And Law, filed December 4, 2005	
	182.	Scantibodies' Reply In Support Of Its Emergency Motion To Stay Injunction Pending Appeal, filed December 5, 2005	
	183.	Scantibodies Clinical Laboratory, Inc. And Scantibodies Laboratory, Inc.'s Witness List & Sixth Supplemental Exhibit List For Damages/Willfulness Trial, filed December 5, 2005	`
	184.	Nichols' Ninth Amended Exhibit List To Memorandum Of Fact And Law, filed December 6, 2005	
	185.	Plaintiff Nichols Institute Diagnostics, Inc.'s First Proposed Supplemental Jury Instructions To The Court's Instructions For The Damages Phase Of The Trial, filed December 13, 2005	
	186.	Order Granting Nichols' Motion For Entry Of Permanent Injunction And Staying Injunction Pending Appeal, filed November 16, 2005	
	187.	Transcript Of Trial Before The Honorable Rudi M. Brewster, Volume VIII December 16, 2005	l
	188.	D'AMOUR et al., J. Clinical Endocrinology & Metabolism (2006) 91(1):283-289	

^{*}EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Date Considered		
Signature Considered	Examiner	